Sunday, November 8, 2026

USD/CNH Over 1% Down In The Last 21 Sessions

ViaNews Editorial Team

August 18, 2024

USD/CNH Over 1% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.51% for the last 21 sessions. At 17:09 EST on Sunday, 18 August, USD/CNH (USDCNH) is $7.16.

USD/CNH's yearly highs and lows, it's 0.004% up from its 52-week low and 0.008% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CNH's Forex is considered to be oversold (<=20).

News about

  • Eur/usd trades with modest gains amid softer usd, remains below 1.1000 mark. According to FXStreet on Friday, 16 August, "Apart from this, expectations that the European Central Bank (ECB) will cut rates again, amid declining inflation in the Eurozone, seem to cap gains for the EUR/USD pair.", "A combination of factors prompts fresh selling around the US Dollar (USD), which, in turn, is seen lending some support to the EUR/USD pair. "
  • Eur/usd price forecast: seems poised to surpass 1.1000 mark and retest YTD peak. According to FXStreet on Friday, 16 August, "Some follow-through selling below the 1.0880 mark might expose the 200-day Simple Moving Average (SMA), currently pegged near the 1.0835 region before the EUR/USD pair drops to the 1.0800 mark.", "The EUR/USD pair builds on the overnight bounce from the 1.0950 area and gains some follow-through traction on Friday, albeit seems to lack bullish conviction. "
  • A very significant change in the eur/usd forecast – commerzbank. According to FXStreet on Friday, 16 August, "Both together mean that we now have to assume that EUR/USD will rise significantly. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com